Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:administeredBy |
oral
|
| gptkbp:alsoKnownAs |
gptkb:regorafenib
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA colorectal cancer hepatocellular carcinoma gastrointestinal stromal tumors |
| gptkbp:ATCCode |
L01XE21
|
| gptkbp:brand |
gptkb:Stivarga
|
| gptkbp:CASNumber |
755037-03-7
|
| gptkbp:developedBy |
gptkb:Bayer
|
| gptkbp:hasMolecularFormula |
C19H15ClF4N4O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
BAY 73-4506
|
| gptkbp:mechanismOfAction |
multi-kinase inhibitor
|
| gptkbp:sideEffect |
diarrhea
fatigue hypertension hand-foot skin reaction |
| gptkbp:target |
gptkb:PDGFR
gptkb:VEGFR gptkb:KIT gptkb:RET RAF kinases |
| gptkbp:usedFor |
treatment of cancer
|
| gptkbp:bfsParent |
gptkb:regorafenib
gptkb:Regorafenib |
| gptkbp:bfsLayer |
7
|